The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to test Novel spectacle lenses in myopic children. The main question it aims to answer are: safety and efficacy of the lenses. Participants will be asked to wear spectacles and participate in eye exams and questionnaires. Researchers will compare Novel spectacle lenses and general single vision spectacle lenses to see if the Novel spectacle lenses correct myopic ametropia, slow the progression of myopia and axial elongation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a 3-year prospective, multicenter, randomized, and single-masked*, parallel-group controlled clinical study. The purpose of this study is to evaluate the safety and efficacy of wearing Novel spectacle lenses to correct myopic ametropia, slow the progression of myopia and axial elongation in myopic children as compared to the use of single vision spectacles lenses.
The treatment arms are:
-
Model A Novel spectacle lens
-
Model B Novel spectacle lens
-
Single vision spectacle lens
Single-masked:
The investigator responsible for conducting ocular data measurements related to the primary and secondary endpoints will be masked. The participants will not be informed the treatment arm during the clinical trial.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Model-A Novel Spectacle lens
|
Device: Novel spectacle lens
wearing spectacle lenses correct myopic ametropia, and may slow the progression of myopia and axial length elongation
|
| Experimental: Model-B Novel Spectacle lens
|
Device: Novel spectacle lens
wearing spectacle lenses correct myopic ametropia, and may slow the progression of myopia and axial length elongation
|
| Other: Single Vision Spectacle lens
|
Device: Single vision spectacle lens
wearing spectacle lenses correct myopic ametropia
|
Outcome Measures
Primary Outcome Measures
- Axial length [24 months]
The difference of Axial length changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants.
- Spherical equivalent cycloplegic autorefraction [24 months]
The difference of spherical equivalent cycloplegic autorefraction changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants
Secondary Outcome Measures
- Axial length [36 months]
- Spherical equivalent cycloplegic autorefraction [36 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant and parent (or guardian) are able and willing to provide consent
-
Participant and parent (or guardian) ensure to attend required study visits and adhere to participant requirements
-
Parent or guardian understands and accepts random allocation of grouping, and that participant and parent (or guardian) will not be told which group participant is allocated to
-
Participant willing to wear the study spectacles lens for a minimum of 12 hours per day for the duration of the study
-
Age at time of parent or guardian consent and participant assent: 8 - 13 years old
-
Spherical equivalent cycloplegic autorefraction: -1.00 to -7.00 D in each eye.
-
Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye
-
Cycloplegic autorefraction anisometropia of 1.50 D or less
-
Monocular best corrected distance visual acuity (BCDVA) equal to or better than logMAR 0.00 in each eye.
Exclusion Criteria:
-
Participant is allergy to fluorescein, benoxinate, proparacaine, tropicamide or cyclopentolate eye drops
-
Any ocular and systemic abnormalities might be expected to affect visual functions or refractive development
-
Have received treatment of myopic control (e.g., orthokeratology, progressive addition lenses, bifocal lenses, medication (e.g., atropine), etc. within 6 months prior to entry into this study.
-
Participant with clinically significant strabismus (including intermittent tropia)
-
Medical history of binocular vision abnormalities
-
Participant with amblyopia
-
Participation in a clinical trial within 30 days prior to entry into this study or during participation
-
Previous intraocular surgery
-
Participant who, in the judgment of the Investigator, presence of any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.
-
Any medical treatment or medication which might have an influence on vision or interfere with study assessments
-
Pathological myopia (myopia that leads to structural changes in the posterior segment of the eye including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Guangzhou Aier Eye Hospital | Yuexiu | Guangzhou | China | |
| 2 | Tianjin Medical University Eye Hospital | Nankai | Tianjin | China |
Sponsors and Collaborators
- HOYA Lens Thailand LTD.
Investigators
- Study Chair: William Zhou, MD, HOYA Lens Thailand LTD.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DG2-3A